Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
10 September 2021 - 10:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2021 (No. 2)
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive
offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
EXPLANATORY NOTE
On September 10, 2021, Cellect
Biotechnology Ltd. (the “Company”), announced a 4:1 ratio change of the Company’s American Depositary Receipt, or ADR,
program. As a result, the number of ordinary shares of the Company represented by each American Depositary Share, or ADS, will be changed
from one hundred (100) ordinary shares to four hundred (400) ordinary shares. The effective date anticipated for the ratio change is September
24, 2021.
ADS holders will be required on
a mandatory basis to surrender their old ADSs to BNY Mellon for cancellation at a rate of one (1) new ADS for every four (4) old ADSs
held. No fractional ADSs will be issued and cash will be paid in lieu of any fractional ADSs resulting from the ratio change. The ratio
change will affect all ADS holders uniformly, will not reduce any ADS holder’s ownership percentage in the Company except for minor
adjustments that may result from the treatment of fractional ADSs and will not result in any change to the Company’s share capital.
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
CELLECT BIOTECHNOLOGY, LTD.
|
|
|
|
Date: September 10, 2021
|
By:
|
/s/ Yaron Ben-Oz
|
|
|
Yaron Ben-Oz
|
|
|
Chief Financial Officer
|
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Apr 2024 to May 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From May 2023 to May 2024